Company ProfilePremium

Oventus Medical Limited

Company Profile Analysis

Ticker: OVN.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Oventus Medical Limited - Company showcase

Year Founded & Workforce

2013

Oventus Medical Limited logo

Oventus Medical Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Oventus Medical Limited Overview

Oventus Medical was a Brisbane-based medical device company that tried to change oral appliance therapy for obstructive sleep apnoea (OSA). Its O2Vent devices combined a mandibular advancement splint with a built-in airway channel. The channel was designed to bypass obstructions at the nose, soft palate and tongue, a patented feature that set it apart from conventional mandibular advancement devices. The product line moved from 3D-printed titanium (O2Vent Mono/T) to 3D-printed medical-grade nylon (O2Vent Optima), with an ExVent valve accessory for harder cases. Commercially, Oventus targeted CPAP-intolerant patients in Australia, the US and Canada. It used a "lab-in-lab" model inside sleep clinics, and later direct-to-consumer telehealth channels. It never moved beyond micro-scale revenue, peaking at about A$1.1M in FY2021, while losing roughly A$6–10M a year. It entered voluntary administration in June 2022, and its IP was sold to a Canadian distributor.


What the company did. Oventus designed, manufactured (or contract-manufactured) and sold custom-fitted oral appliances for OSA and snoring. Every device was made to fit an individual patient's dentition from a scan or impression, then 3D-printed. The distinguishing feature was an integrated airway running through the front of the appliance. The company said this allowed breathing even when the nose was blocked, while the appliance held the jaw forward like a standard mandibular advancement splint (MAS). The company's late-stage descriptions (as summarised by MarketBeat and roic.ai) say that O2Vent Optima addressed the whole upper airway. Its built-in channel bypassed obstruction from the nose, soft palate and tongue, while keeping an oral seal and a stable jaw position. ExVent was a valve accessory that fitted into the airway to regulate exhalation for harder-to-treat cases.

Company's own description (latest available). Earlier ASX disclosures described Oventus as an Australia-based medical device company commercialising a suite of oral appliances for sleep apnoea and snoring. They also described its principal activities as commercialising and distributing the O2Vent in Australia and developing a product pipeline for segments of the snoring and sleep apnoea market. By 2020, the company described itself as an "obstructive sleep apnoea treatment innovator" marketing products under the O2Vent Optima brand (SmallCaps, 2020).

Business model evolution (independent characterisation). The model went through three phases:

  1. Dentist channel (2016–2018). Devices were sold to dentists in Australia and, after the January 2017 US pilot launch, in the US. A US subsidiary (Oventus Medical USA, Delaware) and an FDA-registered US dental lab contract manufacturer supported this (ASX release, 18 Jan 2017).

  2. "Lab-in-lab" sleep-clinic model (2019–2021). Oventus placed its dental sleep service inside sleep physician groups and durable medical equipment (DME) providers. The aim was to capture CPAP-intolerant patients at the point of diagnosis rather than relying on referrals to dentists. Partners included Aeroflow Healthcare, Delaware Sleep Disorder Centres, Reliable Respiratory, Careica Health, Specialized Sleep, PEAKsleep, Tri Hospital Sleep and Ontario Sleep Care. At one point 36 sites were contracted, with 14 live by early 2020 (HME News, April 2020).

  3. Direct-to-consumer and telehealth (2021–2022). Patients were sold to through o2vent.com, gopapfree.com and awakexpress.com, with a "virtual patient journey" supported by telehealth (HME News, Aug 2021 and Feb 2022).

Revenue model mix. Revenue was almost entirely product-based: device sales per patient and consumables (ExVent resupply packs, connector bands). There was some service revenue embedded in lab-in-lab arrangements, but a split between product, service and subscription was not publicly disclosed. ExVent "Annual Resupply Packs" gave a nascent recurring consumable stream (product list in the Nov 2022 Canadian distribution agreement).

Value chain position. Oventus owned the IP and product design. It ran a 3D-printing manufacturing operation in Australia (Oventus Manufacturing Pty Ltd) and used a US contract dental lab. Later it held the clinical delivery model (lab-in-lab) and patient acquisition (DTC). In effect it was vertically integrated from design to patient, which is capital-intensive for a company with sub-A$1.1M revenue.

Customer types. These were dentists (dental sleep medicine practitioners), sleep physician groups and sleep labs, DMEs and home medical equipment providers (e.g., Aeroflow), Medicare and commercial payers in the US (through PDAC coding), and consumers directly.

End-markets. The end-markets were the treatment of OSA and snoring, specifically the CPAP-intolerant and CPAP-non-adherent segment. At IPO the company estimated the global sleep apnoea therapeutic device market at US$3.5B, growing 7.4% a year (Business News Australia, June 2016).

Strategy

The company's strategy is now historical. The last stated themes (FY2021 results and the 1H FY2022 update) were:

Expand the lower-cost "virtual lab-in-lab" program: with new and existing national partners in FY2022 (HME News, Aug 2021).

Shift to direct-to-consumer marketing: to build the patient pipeline, then improve conversion and reduce friction points in the patient journey (CEO John Cox, Feb 2022).

Position O2Vent Optima as the first choice for OSA treatment: through clinical and scientific research led by the Scientific Advisory Board (Jan 2022).

Use the 2021 capital raise: to strengthen the balance sheet, improve manufacturing and logistics, expand sales and marketing, and fund one-off restructuring to lower operating expenses (HME News).

Regain Medicare reimbursement: for the revised Optima version through PDAC re-application.

Medium-term financial targets: none publicly disclosed. ESG commitments: none disclosed. Current strategy: not applicable (entity defunct). The successor owner OADS states it is expanding to serve sleep patients and professionals globally under its own brand (Sleep Review, 2023).

Products & Services

Service and channel offerings:

The Canadian distribution agreement of November 2022 listed six products (Optima, Optima Mini, ExVent Multipack, ExVent Annual Resupply Packs, Connector Bands, Bite Fork). That list represents the final commercial catalogue.

Product Portfolio

ProductDescription and key specificationsTarget customerLaunch / clearancePricing

O2Vent (original / "Clearway")

Custom oral appliance with an integrated airway, 3D-printed in titanium (CSIRO Lab 22 prototype). Bypasses nasal, soft palate and tongue obstruction

OSA and snoring patients in Australia

TGA listed about 2015–16. FDA 510(k) April 2016

—

O2Vent Mono

First commercial range. Metal 3D-printed, monobloc design. Served as the regulatory platform for later models

Australian dentists and patients

FDA-cleared by mid-2016

—

O2Vent T

Next-generation titratable device (adjustable mandibular advancement) with airway

US dentists (launch product)

510(k) lodged 2016. US launch Jan 2017

—

O2Vent Optima

Flagship product. Customisable 3D-printed medical-grade nylon appliance. Manages the whole upper airway through a patented built-in channel, keeps an oral seal and stable jaw position. Indicated for mild, moderate and severe CPAP-intolerant OSA and snoring, including nasal obstruction

CPAP-intolerant patients through sleep clinics, DMEs, dentists and DTC

FDA clearance about 2020. PDAC Medicare coding approval early 2020 (re-application later for revised version). US DTC launch Feb 2021

Not publicly disclosed. Revenue per unit rose 42% in 1H FY22 (HME News)

O2Vent Optima Mini

Smaller-format Optima variant

Patients with smaller oral anatomy (inferred)

——

ExVent (Multipack – Titration)

Valve accessory that inserts into the Optima airway to regulate nasal and oral exhalation, aimed at harder-to-treat cases

Optima users with residual apnoea

Not publicly disclosed (by 2020)

—

ExVent Annual Resupply Packs

Consumable replacement valves

Existing ExVent users

—

Not publicly disclosed (recurring consumable)

Oventus Connector Bands

Consumable/accessory components for the appliance

Existing users

——

Oventus Bite Fork

Clinical accessory for capturing bite registration

Clinicians

——

CPAP connectivity (airway–CPAP interface)

The airway was clinically studied as an interface for lower-pressure CPAP ("CPAP requirements when connected to the Oventus airway")

Combination-therapy patients

Clinical data presented in 2017

Not commercialised as a separate SKU (not publicly disclosed)

“—” = not publicly disclosed.

OfferingDescriptionPeriod

Lab-in-lab

Dental sleep service embedded in sleep clinics and DMEs, using scanning in the clinic to produce the appliance

2019–2022

Virtual lab-in-lab / telehealth

Lower-cost remote version with national partners

FY2021–FY2022

DTC websites

o2vent.com, gopapfree.com, awakexpress.com

2021–2022

Financial Narrative

Basis: FY2017–FY2021 annual figures (years ended 30 June) from Stockopedia and Moomoo summaries of the annual reports (IFRS, AUD). These are aggregators summarising the annual reports, not the primary filings. The FY2022 annual report was never issued in normal form because administration began in June 2022, so 1H FY2022 is the last reported period. "n/a" means not publicly disclosed in verifiable sources.

Margins (%)

Margins are computed from the table above. Revenue CAGR FY2017–FY2021 is about 19.4% using the A$0.537M base, or about 24.9% using the A$0.448M base. FY2018–FY2021 CAGR is about 59%.

Interim trend: notes and sources

Sources: Investing.com financial summary and Motley Fool (1H FY20 loss A$5.1M). The aggregator's "Jun 2021" and "Jun 2020" columns are 12-month figures.

Balance sheet

At 31 December 2021 (1H FY2022), total assets were A$9.86M, liabilities A$1.87M and equity A$7.99M. Equity fell by A$4.6M in six months, in line with the A$5.1M half-year loss. The company carried negligible financial debt, and its liabilities were mainly payables, provisions and leases (breakdown not publicly disclosed). By February 2021 the accumulated losses had reached A$37.3M (Motley Fool).

Cash flow

In 1H FY2022, operating cash flow was −A$4.48M, investing −A$0.09M, financing −A$0.30M, and net change in cash −A$4.81M. Operating cash burn accelerated to an annualised rate of about A$9M, with no new equity raised in the half. This was the immediate cause of the June 2022 failure. Capex is not separately disclosed, so investing cash flow is used as a proxy.

Ratios

ROIC, current ratio, net debt/EBITDA, interest coverage and cash conversion cycle are not meaningful or not publicly disclosed. EBITDA was deeply negative, there was no material interest-bearing debt, and working capital details are unavailable.

Commentary. The financial record is that of a pre-commercial medtech that never reached scale. Revenue fell after the FY2017 launch quarter (FY2018: A$0.27M), recovered slowly in FY2019–FY2020, then grew 160% in FY2021 to about A$1.1M as lab-in-lab sites and DTC channels matured. Even at that peak, operating expenses of about A$11M were roughly ten times revenue. Gross margin peaked at 52% in FY2019 and then fell to 37% in FY2021, as COVID-era volumes, the nylon transition and channel economics (partner revenue share in lab-in-lab) diluted unit profitability. 1H FY2022 gross margin recovered to about 52% on higher revenue per unit (+42%), consistent with the DTC shift. Revenue was flat, however, and losses widened.

Survival depended on equity markets. The company raised A$12M at IPO (2016), about A$6.5M (2017/18), about A$9.3M (2020) and about A$10M (2021). Financing inflows of A$14.8M in FY2020 and A$9.2M in FY2021 were consumed within about 18 months. The share price fell from A$0.50 (IPO) to about A$0.02, which made further dilutive raises effectively impossible by mid-2022.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityJurisdictionFunctionFate

Oventus Medical Limited

Australia

Listed parent, IP holder

Administration (Jun 2022), then liquidation (reported Jan 2023), delisting (reported Jul 2023), deregistration (reported Sep 2024)

Oventus Manufacturing Pty Ltd

Australia

Manufacturing and distribution, IP co-owner

Under administration. Sold to Crystalaid Manufacture Pty Ltd (Feb 2023)

Oventus CRM Pty Ltd

Australia

Customer relationship and sales entity (function inferred from name)

Under administration. Outcome not publicly disclosed

Oventus Medical USA (Inc.)

Delaware, USA

US commercial operations

Operations ceased Jun 2022. Legal status not publicly disclosed

Revenue by Segment

Segment metric1H FY20211H FY2022

Australia segment revenue (AUD Mn)

0.1340.179

North America segment revenue (AUD Mn)

0.4160.375

Australia segment loss (AUD Mn)

-2.24-2.4

North America segment loss (AUD Mn)

-2.06-2.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement

MetricFY2017FY2018FY2019FY2020FY2021

Revenue (AUD Mn)

0.5370.2710.3320.4191.09

Gross profit (AUD Mn)

-0.0460.0940.1740.1880.402

Total operating expenses (AUD Mn)

7.16.428.4910.711

Operating income (AUD Mn)

-6.56-6.15-8.15-10.2-9.96

Pre-tax income (AUD Mn)

-6.51-5.87-7.85-10.1-9.83

Net income (AUD Mn)

-6.51-5.87-7.85-10.13-9.83

Dividends per share (AUD)

00000

Margin Analysis (%)

MetricFY2017FY2018FY2019FY2020FY2021

Gross margin (%)

-8.634.752.444.936.9

Operating margin (%)

-1,221.6-2,269.4-2,454.8-2,434.4-913.8

Net margin (%)

-1,212.3-2,166.1-2,364.5-2,417.7-901.8

Financial Analysis

Metric1H FY2020FY2020 (12M)1H FY2021FY2021 (12M)1H FY2022

Revenue

—0.420.551.090.554

Gross profit

—0.190.250.400.29

Operating income

—-10.2-4.47-9.96-5.07

Net income

-5.1-10.13-4.68-9.83-5.14

Balance Sheet

MetricFY2020FY2021

Total assets (AUD Mn)

14.3315.08

Total liabilities (AUD Mn)

2.112.46

Total equity (AUD Mn)

12.2212.62

Cash Flow

MetricFY2017FY2018FY2019FY2020FY2021

Operating cash flow (AUD Mn)

———-7.67-6.92

Investing cash flow (AUD Mn)

———-1.51-1.53

Financing cash flow (AUD Mn)

———14.769.18

Net change in cash (AUD Mn)

———5.460.7

Free cash flow proxy, OCF + investing (AUD Mn)

———-9.18-8.45

Dividends paid (AUD Mn)

00000

Buybacks (AUD Mn)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2020FY2021

ROE (%) — FY2021 on average equity

—-79.1

ROA (%) — FY2021 on average assets

—-66.8

Asset turnover (x)

0.030.07

Liabilities / equity (x)

0.170.19

Revenue by Region

Region1H FY20211H FY2022

Australia revenue (AUD Mn)

0.1340.179

North America revenue (AUD Mn)

0.4160.375

Total revenue (AUD Mn)

0.550.554

Valuation Snapshot

MetricValue

IPO price (Jul 2016)

A$0.50

First-day trade

About A$0.69

Later placement prices

About A$0.36 (2017/18). About A$0.485 traded in 2020 (SmallCaps)

Last traded price (pre-suspension, 2022)

About A$0.02

Price change, IPO to last trade

About −96%

1-year change before suspension

About −83% (Stockopedia)

Market cap at last trade

About A$4.83M (MarketBeat, stale)

Current market cap

Nil (delisted)

P/E, EV/EBITDA, EV/Sales, P/B

Not meaningful (loss-making; delisted)

Analyst consensus

Not applicable. A stale "Strong Buy" label on Stockopedia should be disregarded

Dividends

None ever paid

Credit ratings

None (unrated)

Debt maturities

No material financial debt

Metric

FY2017

Equity raised (AUD Mn, approx.)

12

Analyst Conclusions

Management guidance / consensus. None. The entity is dissolved (reported) and there is no continuing listed security.

Bull-case arguments (retrospective: what could have worked):

  1. The airway IP was genuinely differentiated and remains commercially alive under OADS, so the technology may yet find its market.

  2. Unit economics were improving in DTC (revenue per unit +42% in 1H FY22) and gross margin recovered to about 52%.

  3. Channel validation came from credible partners (Aeroflow, Canadian sleep groups) and from Medicare coding.

Bear-case arguments (what happened):

  1. Revenue never exceeded A$1.1M a year while costs ran at about A$10–11M, so the company was structurally dependent on dilutive capital.

  2. Repeated model pivots spread a small team across manufacturing, clinical delivery and consumer marketing at the same time.

  3. When capital markets closed and the founder left, the governance and funding base collapsed within weeks.

Monitorables (next 12 months). For former shareholders, the only items are confirmation of deregistration on ASIC Connect and any final liquidator reports (tax-loss documentation). For the technology, watch OADS's commercial progress with the O2Vent and ExVent products in Canada and globally.

Analyst verdict. Oventus Medical is a textbook case of a clinically interesting medtech that could not bridge the gap between regulatory clearance and commercial scale. Its core idea, an oral appliance with an integrated airway able to bypass obstruction at the nose, palate and tongue, was novel, patented and cleared by the FDA several times. Yet over five full fiscal years the company generated cumulative revenue of only about A$2.6M, against cumulative net losses of about A$40M (FY2017–FY2021: A$6.51M, A$5.87M, A$7.85M, A$10.13M and A$9.83M, plus A$5.14M in 1H FY2022). Each of its strategic pivots was individually sensible: from selling to dentists, to embedding in sleep clinics, to telehealth, to direct-to-consumer. Together they prevented any single channel from reaching scale, while the company carried the fixed costs of an Australian manufacturing plant and a US commercial organisation.

COVID-19 hit at the worst possible moment, just as the lab-in-lab model was gaining traction in early 2020 with 14 of 36 contracted sites live. The pandemic shut the in-person clinic footfall the model needed. Reimbursement friction (the Optima PDAC re-application) added further drag in the core US market. By 1H FY2022 the company was burning about A$9M a year on flat revenue, with a share price of about A$0.02 that ruled out further raises. The founder's resignation and the board's inability to maintain quorum led directly to administration in June 2022.

The outcome for equity holders was a total loss. The IP sold for A$500,000 against more than A$37M of accumulated losses. For investors, the transferable lessons concern capital intensity, channel focus and reimbursement-first commercialisation in dental sleep medicine. The O2Vent technology itself lives on privately under Open Airway Dental Solutions. Verdict: not investable. The entity no longer exists.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenureBackground

Dr Mel Bridges

Chair at IPO, later non-executive director (still a director in Nov 2022)

2016–administration

Veteran Australian biotech/medtech chair and investor. Age and education not publicly disclosed in verified sources

Sue MacLeman

Chair

At least 2021–2022

Life sciences director. Details not publicly disclosed in verified sources

Neil Anderson

CEO

c. 2016–c. 2019

Led the IPO-era and US launch (Jan 2017)

Dr Chris Hart (MPhil, BSc, BDSc)

Founder, inventor; Clinical Director, then CEO/MD, then Executive Director and Chair of the Scientific Advisory Board

Founder to 8 Jun 2022 (CEO c. 2019 to 31 Jan 2022)

Dentist and OSA sufferer who invented the O2Vent

John Cox

CEO

1 Feb 2022 to administration

Medtech commercialisation background, including OSA therapeutics (per company)

Michael Sisk

VP Finance (US)

2021–2022

—

Elise Hogan

VP (clinical/US, title partly cited)

c. 2017

Clinician

Michael McCann and Graham Killer (Grant Thornton)

Voluntary administrators, later liquidators

Jun 2022 onward

External administrators

“—” = not publicly disclosed.

Competitive Landscape

Key Competitors

CompetitorSegmentRelevance

ResMed (NYSE: RMD / ASX: RMD)

CPAP (standard of care), masks, digital health

Dominant OSA therapy provider, against which oral appliances compete for CPAP-intolerant patients

Philips Respironics

CPAP

Major CPAP rival (affected by the 2021 recall)

Fisher & Paykel Healthcare

CPAP masks and humidification

CPAP ecosystem

Inspire Medical Systems

Hypoglossal nerve stimulation

Leading CPAP-alternative therapy for moderate-to-severe OSA

SomnoMed (ASX: SOM)

Custom mandibular advancement devices (SomnoDent)

Most direct listed oral-appliance peer, also Australian

ProSomnus

3D-printed precision oral appliances

Direct US peer using digital manufacturing

Glidewell Laboratories

Dental lab oral appliances (e.g., Silent Nite, EMA)

High-volume, low-cost competitor

Panthera Dental

CAD/CAM-milled oral appliances

Direct competitor in Canada and the US

Vivos Therapeutics

Oral appliances and airway remodelling

US DTC/dental-channel peer

Zephyr Sleep Technologies, other dental labs

Oral appliance titration and devices

Niche

Peer Comparison FY2021

CompanyFYRevenueGrowthGross marginNotes

Oventus Medical

FY2021 (Jun)

A$1.09M

+160%36.9%

Operating margin about −914%

Recent Developments

There has been no corporate newsflow in the past 18 months (April 2025 to October 2026), as the entity is defunct.

That cannot be met with verified events, and none have been invented.

Company Snapshot

$0.8M

Revenue

2013

Founded

Indooroopilly, Australia

Headquarters

SWOT Analysis

Strengths

  • Patented, differentiated airway design: Worldwide patent portfolio, later bought by OADS (Jan 2023)
  • Multiple FDA 510(k) clearances: O2Vent (Apr 2016), O2Vent T (2016–17), O2Vent Optima (2020)
  • Medicare coding achieved for Optima: PDAC approval reported Apr 2020
  • Improving unit economics in DTC: Revenue per unit +42% in 1H FY22
  • Credible founder-inventor clinical voice: Dr Hart presented clinical results in the US (2017)
  • Healthy gross margins at small scale: 52% in FY2019 and about 52% in 1H FY22

Weaknesses

  • Micro-scale revenue: Peak of A$1.09M in FY2021
  • Extreme operating losses: A$6–10M a year over FY2017–FY2021
  • Cash burn far above revenue: 1H FY22 operating cash flow of −A$4.48M against A$0.55M revenue
  • Strategy churn: Dentist, then lab-in-lab, then virtual, then DTC within about five years
  • Reimbursement gaps: Optima re-application to PDAC (2021)
  • Leadership instability: Three CEOs in about six years. Founder resigned 8 Jun 2022

Opportunities

  • CPAP-intolerant population: Company indication targeted mild-to-severe CPAP-intolerant OSA
  • Philips CPAP recall displacing patients: Recall in 2021, during the DTC push
  • DME channel scale through Aeroflow: Plans for a national rollout after the initial seven sites
  • Canadian sleep-group adoption: Tri Hospital, Ontario Sleep Care, PEAKsleep
  • Recurring consumables: ExVent annual resupply packs
  • Telehealth normalisation: Virtual lab-in-lab and DTC sites

Threats

  • COVID-19 clinic closures: Management cited reduced North American footfall (Feb 2021)
  • Capital-market dependence: Four equity raises. Share price fell from A$0.50 to about A$0.02
  • Better-capitalised competitors: ResMed, Inspire, SomnoMed, ProSomnus
  • Reimbursement and coding risk: Version-specific PDAC approval
  • Governance fragility: Insufficient directors triggered the Jun 2022 suspension
  • Insolvency: Administration Jun 2022, then liquidation (reported Jan 2023)

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Feb 2021O2Vent Optima launched in the US through GoPAPfreeStart of DTC strategy
22 Feb 20211H FY21: revenue A$550K (+192%), cash receipts A$416K (+109%), device sales +143%Best half on record
Feb 2021Four new lab-in-lab sites (Careica ×2, Specialized Sleep, PEAKsleep)Network growth
Feb 2021VGM Group first member expected to go live within 90 daysChannel access
2021Placement (about A$5M) plus 1-for-4.4 entitlement offer (about A$5M)Last major equity raise
2021Re-application to PDAC for the revised Optima, with Medicare reimbursement temporarily unavailable for that versionUS reimbursement setback
2021Michael Sisk appointed VP Finance (US)US finance build-out
31 Aug 2021FY21 revenue about A$1.1M (+160%)Peak annual revenue
Q1 FY22 (Oct 2021)Quarterly revenue A$221K, flat on the prior quarterGrowth stalls
31 Jan 2022John Cox named CEO from 1 Feb. Q2 FY22 revenue A$334K (+51%)Leadership change
28 Feb 20221H FY22: revenue A$554K, cash receipts A$497K (+20%), revenue per unit +42%, net loss A$5.1MBurn rising
8 Jun 2022Founder Dr Chris Hart resignsGovernance breakdown
9 Jun 2022ASX trading suspended (insufficient directors)Pre-insolvency
14/28 Jun 2022Grant Thornton appointed voluntary administrators. US production halted, staff laid offInsolvency
Jul 2022Expressions of interest process, with offers due 27 Jul 2022Sale or recapitalisation attempt
2 Nov 2022OADS appointed exclusive Canadian distributorInterim trading
20 Jan 2023Creditors told the company has entered liquidation (as reported)Terminal
31 Jan 2023IP sold to OADS for A$500KAsset realisation
Feb 2023Oventus Manufacturing sold to Crystalaid (A$10K plus A$430K DOCA)Asset realisation
Jul 2023Delisted from ASX (reported)End of listing
Sep 2024Deregistered by ASIC (reported)Entity ceases to exist

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Revenue by Segment: Australia segment revenue rose from AUD 0.1 Mn in 1H FY2021 to AUD 0.2 Mn in 1H FY2022.
Oventus Medical Limited — Revenue by Segment
Series (AUD Mn)1H FY20211H FY2022
Australia segment revenue0.10.2
North America segment revenue0.40.4
Australia segment loss-2.2-2.4
North America segment loss-2.1-2.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.